Trial reportPediatric nephrology (Berlin, Germany)2008
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Trial report in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04494438 (Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome), which is not on this map. Cited by 123 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rituximab in Patients With Low Dose Steroid-dependent Idiopathic Nephrotic Syndrome
Who cites it
123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Medicine · 2016Pooled it
- The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.Scientific reports · 2015Pooled it
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Trial
- Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.Medicine · 2018Trial
- Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Trial
- The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome.European journal of pediatrics · 2016Trial
- Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.BMJ case reports · 2015Trial
- Rituximab in children with resistant idiopathic nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2012Trial
- Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.Clinical journal of the American Society of Nephrology : CJASN · 2011Trial
- Rituximab for refractory cases of childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Trial
- Rituximab efficiency in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2009Trial
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase.Medicine · 2025Observational
- Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions.Pediatric nephrology (Berlin, Germany) · 2025Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several case reports suggest that rituximab (RTX) could be effective in steroid-dependent nephrotic syndrome, but RTX efficacy has not yet been studied in a series of patients. Safety and efficacy of RTX were assessed in a multicenter series of 22 patients aged 6.3-22 years with severe steroid-dependent nephrotic syndrome or steroid-resistant but cyclosporin-sensitive idiopathic nephrotic syndrome. Patients were treated with two to four infusions of RTX. Seven patients were nephrotic at the time of RTX treatment. Peripheral B cells were depleted in all subjects. Remission was induced in three of the seven proteinuric patients. One or more immunosuppressive (IS) treatments could be withdrawn in 19 patients (85%), with no relapse of proteinuria and without increasing other IS drugs. RTX was effective in all patients when administered during a proteinuria-free period in association with other IS agents. When relapses occurred, they were always associated with an increase in CD19 cell count. Adverse effects were observed in 45% of cases, but most of them were mild and transient. This study suggests that RTX could be an effective treatment for severe steroid-dependent nephrotic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.